Suppr超能文献

表柔比星在转移性乳腺癌(VEC)和晚期卵巢癌(PEC)联合化疗中的应用

[Epirubicin in combination chemotherapy of metastasized breast cancer (VEC) and advanced ovarian cancer (PEC)].

作者信息

Christmann D

出版信息

Onkologie. 1986 Aug;9 Suppl 1:11-2. doi: 10.1159/000216055.

Abstract

Epirubicin was applied in combination with vincristine and cyclophosphamide (VEC) against metastatic cancer of the breast in 14 patients, against advanced cancer of the ovaries. Epirubicin was applied in combination with cisplatin and cyclophosphamide (PEC) in 12 patients. Treatment of metastatic cancer of the breast achieved retrogression in 64%, the tumor was brought to a standstill in 12%. Treatment of cancer of the ovaries achieved complete retrogression in 75%, the tumor was brought to a standstill in 8.3%. There was no incidence of considerable myelo- or cardiotoxic side effects resulting in a necessary interruption of treatment. The achieved results of this treatment correspond to those with doxorubicin combinations, the toxicity, however, is less.

摘要

表柔比星与长春新碱和环磷酰胺(VEC)联合应用于14例转移性乳腺癌患者以及晚期卵巢癌患者。表柔比星与顺铂和环磷酰胺(PEC)联合应用于12例患者。转移性乳腺癌的治疗使64%的患者病情消退,12%的患者肿瘤停止发展。卵巢癌的治疗使75%的患者完全消退,8.3%的患者肿瘤停止发展。未出现导致治疗必须中断的严重骨髓或心脏毒性副作用。该治疗所取得的结果与阿霉素联合治疗的结果相当,然而毒性较小。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验